Polyclonal antibodies, used for both induction and rejection therapy in renal transplant recipients, are associated with such side effects as chills and fever. We describe two patients who developed a coagulopathy during antithymocyte globulin (ATGAM) therapy, a previously unknown complication. The laboratory tests revealed prolonged prothrombin and partial thromboplastin times and thrombocytopenia. Discontinuation of ATGAM therapy resulted in correction of these abnormalities.
ShieldCFIII, CosimiA.B., Tolkoff-RubinN., RubinR.H., HerrinJ., RussellP.S.. Use of antilymphocyte globulin for reversal of acute allograft rejection.Transplantation1979; 28: 461–4.
3.
HardyM.A., NowygardR., ElbergA., AppelG.. Use of ATG in treatment of steroid resistant rejection.Transplantation1980; 29: 162–4.
CosimiA.B.. The clinical value of antilymphocyte antibodies.Transplant Proc1981; 13: 462–8.
9.
RappaportS.I.. Thrombotic mechanisms and antithrombotic therapy. In: RappaportS.I., ed. Introduction to hematology.2nd ed.Philadelphia, JB. Lippencott Company1987; 566–7.
10.
AnsellJ.A.. Antithrombotic therapy. In: AnsellJ.A., ed. Handbook of hemostasis and thrombosis. A diagnostic and therapeutic approach.1st ed.Boston, Little Brown and Company1986; 73.
